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AbstrAct
Colorectal cancer (CRC) is the third most common cancer causing high mortality 
rates world-wide. Delineating the molecular mechanisms leading to CRC development 
and progression, including the role of microRNAs (miRNAs), are currently being 
unravelled at a rapid rate. Here, we report frequent downregulation of the microRNA 
miR-320 family in primary CRC tissues and cell lines. Lentiviral-mediated re-expression 
of miR-320c (representative member of the miR-320 family) inhibited HCT116 CRC 
growth and migration in vitro, sensitized CRC cells to 5-Fluorouracil (5-FU), and 
inhibited tumor formation in SCID mice. Global gene expression analysis in CRC cells 
over-expressing miR-320c, combined with in silico prediction identified 84 clinically-
relevant potential gene targets for miR-320 in CRC. Using a series of biochemical 
assays and functional validation, SOX4, FOXM1, and FOXQ1 were validated as novel 
gene targets for the miR-320 family. Inverse correlation between the expression 
of miR-320 members with SOX4, FOXM1, and FOXQ1 was observed in primary CRC 
patients’ specimens, suggesting that these genes are likely bona fide targets for the 
miR-320 family. Interestingly, interrogation of the expression levels of this gene panel 
(SOX4, FOXM1, and FOXQ1) in The Cancer Genome Atlas (TCGA) colorectal cancer 
data set (319 patients) revealed significantly poor disease-free survival in patients 
with elevated expression of this gene panel (P-Value: 0.0058). Collectively, our data 
revealed a novel role for the miR-320/SOX4/FOXM1/FOXQ1 axes in promoting CRC 
development and progression and suggest targeting those networks as potential 
therapeutic strategy for CRC.
INtrODUctION
Colorectal cancer (CRC) is the third most common 
type of cancer in incidence, as well as the fourth most 
common cause of death for both genders around the 
globe [1]. Conventional chemotherapeutic strategies for 
CRC involves the use of highly toxic drugs with many 
undesirable side-effects [2, 3], underscoring the need to 
identify novel biomarkers or combinational therapies for 
early diagnosis, as well as improved disease stratification 
and treatment choices. Recently, it was shown that gene 
expression is orchestrated at the posttranscriptional level 
by small noncoding RNA species. One prominent class 
of noncoding RNAs are microRNAs (miRNAs) that have 
been intensely investigated in various biological systems 
[4]. Inter-regulation between messenger RNA (mRNA) 
and miRNA is a complex cellular process; insights into 
these interactions facilitate the understanding of the 
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fine-tuning of transcriptional and translational outputs, 
and developmental processes [5]. MiRNAs have been 
implicated in a myriad of fundamental cellular and 
physiological processes including cellular differentiation, 
proliferation, survival, motility, apoptosis and stem cell 
maintenance [6-8]. Using mRNA-miRNA transcriptomics 
data in conjunction with in silico target prediction 
algorithms, plus functional validation studies is a potent 
strategy for the identification of novel mRNA-miRNA 
regulatory networks in different human diseases [9-11]. 
Over the past decade, aberrant expression of 
different miRNAs (oncomiRs and tumor suppressor 
miRNAs) have been implicated in driving colorectal 
cancer progression [8, 10, 12-14]. In particular, our recent 
data have revealed over 700 potential miRNA-mRNA 
regulatory networks in colorectal cancer [10]. Notably, the 
expression level of miR-320 family (miR-320a, -b, -c, -d 
and -e) were significantly down-regulated in CRC samples 
compared to adjacent normal mucosa [10]. 
While the miR-320 family has been described to 
be involved in several different human malignancies [15-
19], to date however; the role of the miR-320 family in 
CRC has not been fully elucidated. Herein, we took an 
unbiased approach and identified the biologically and 
clinically-relevant gene targets for miR-320 family in 
CRC. Lentiviral-mediated re-expression of miR-320c 
(representative member of the miR-320 family) inhibited 
CRC growth in vitro and in vivo, and sensitized CRC cells 
to 5-Fluorouracil (5-FU). Global gene expression analysis, 
in silico prediction, and functional validation revealed 
SOX4, FOXM1, and FOXQ1 as novel gene targets for 
miR-320 family. We observed an inverse correlation 
between the expression of miR-320 members with SOX4, 
FOXM1, and FOXQ1 in CRC patients’ specimens, 
strongly indicating that those genes are bona fide targets 
for miR-320 family.
rEsULts
Mir-320 family is downregulated in crc and 
their overexpression reduces Hct116 cell growth 
and migration
Our previous miRNA expression profiling in CRC 
compared to adjacent normal tissues revealed multiple 
dysregulated miRNAs, including downregulation of the 
miR-320 family (miR-320a, -b, -c, -d, and -e) (Figure 
1a) [10]. MiR-320c was subsequently used to represent 
the miR-320 family in the subsequent functional studies 
conducted using the HCT116 CRC model, which have 
low levels of miR-320 expression (Supplementary Figure 
1). Lentiviral-mediated stable expression of miR-320c 
reduced the viability of HCT116 colon cancer cells 
in vitro (Figure 1b and 1c). Similar results were also 
observed when hsa-miR-320c was over-expressed in the 
SW620 and HCT8 CRC cell lines (Supplementary Figure 
2). Similar inhibitory effects were observed when hsa-
miR-320a was over-expressed in the SW620 and HCT8 
CRC cell lines (Supplementary Figure 3). Real-time 
proliferation assay revealed a significant reduction in 
the growth of miR-320c-HCT116 cells compared to LV 
control cells during 100-hour observation period (Figure 
1d). Concordantly, the clonogenic assay also revealed 
lower number of colonies in the miR-320c-HCT116 
compared to LV control cells (Figure 1e), suggesting a 
strong inhibitory effect of miR-320c on colony formation 
in the HCT116 model. Similar inhibitory effects were 
observed on cell migration toward media containing 10% 
FBS in the miR-320c HCT116 compared to LV control 
cells employing two independent assays: microelectroic 
sensor plate assay (Figure 1f) and transwell assay (Figure 
1g), implicating a role for this miRNA in migration as well 
as in proliferation. 
Multiple dysregulated pathways in mir-320c 
Hct116 cells
To unravel the molecular and cellular processes 
regulated by miR-320c, we performed global mRNA 
expression profiling comparing miR-320c HCT116 with 
LV Control cells. As shown in Figure 2a, hierarchical 
clustering based on differentially-expressed mRNAs 
revealed clear separation of the two groups. Using 
significance analysis, we observed 3844 downregulated 
transcripts in miR-320c HCT116 cells (Supplementary 
Table 1). The distribution of the top 10 enriched pathway 
designations for the downregulated genes in miR-320c 
HCT116 cells are shown in Figure 2b, indicating a role 
for miR-320c in regulating cell cycle, DNA replication, 
DNA damage response, and integrated cancer pathways. 
Illustration of the cell cycle pathway is presented in panel 
Figure 2c, with matched entities highlighted. 
In order to identify the biologically and clinically 
relevant gene targets for miR-320 family in CRC, we 
focused on the list of genes that were downregulated in 
miR-320c HCT116 cells, that were predicted to be targeted 
by miR-320 family using in silico prediction (TargetScan), 
and those that were also upregulated in primary CRC 
specimens based on microarray gene expression profiling. 
Using this strategy, we identified 84 genes as potential 
miR-320 targets in CRC (Figure 3a, Supplementary 
Table 2). The expression levels of a selected number 
of these genes (FOXQ1, FOXM1, HMGB3, RUNX1, 
MKI67, ZWILCH, E2F1 and SOX4) was subsequently 
validated using qRT-PCR (Figure 3b). siRNA-mediated 
knockdown of several of those genes (FOXM1, FOXQ1, 
HMGB3, MKI67, RUNX1, SOX4, and ZWILCH) led to 
a significant reduction in HCT116 cell viability, similar 
to those observed when miR-320c was over-expressed in 
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Figure 1: mir-320 family is downregulated in crc and it suppresses crc cell proliferation, migration and 
clonogenicity. a. Expression of miR-320a, -b, -c, -d, and e in CRC (Log2) compared to adjacent normal tissue based on microarray data. 
Data are presented as mean ± S.E., n = 13. b. qRT-PCR quantification of hsa-miR-320c expression in miR-320c HCT116 compared to LV 
control cells. Data are representative of three experiment and are presented as mean ± S.D., n = 3. c. Lentiviral-mediated re-expression of 
miR-320c in HCT116 cells reduces their cell viability. d. Real time proliferation assay revealed significant decrease in the proliferation of 
miR-320c HCT116 compared to LV control cells in a time-dependent manner. e. Clonogenic assay showing remarkable reduction in the 
colony forming capability of miR-320c HCT116 cells compared to LV control cells. Plates were stained with Diff-Quik stain set on day 10. 
Wells are representative of two independent experiments for each condition. f. and g. Real time and conventional migration assay showing 
significant inhibition of cell migration in the miR-320c HCT116 compared to LV control cells. The two-tailed t-test was used to compare 
different treatment groups. ***p < 0.0005.
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Figure 2: mir-320c regulated multiple cellular processes in Hct116 cells. a. Hierarchical clustering of miR-320c HCT116 vs 
LV control HCT116 cells based on differentially expressed mRNA levels. Each column represents one replica and each row represents a 
transcript. Expression level of each gene in a single sample is depicted according to the colour scale. b. Pie chart illustrating the distribution 
of the top 10 pathway designations for the downregulated genes in miR-320c HCT116 cells. The pie size corresponds to the number of 
matched entities. c. The integrated cell cycle pathway is illustrated in panel c.
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Figure 3: Identification of the clinically-relevant miR-320c target genes in CRC. a. Venn diagram depicting the overlap 
between the predicted gene targets for miR-320c (based on TargetScan algorithm) vs the downregulated genes in miR-320c HCT116 cells 
and the differentially upregulated genes in CRC identified from microarray gene expression. b. The expression levels of selected genes 
that were common to all gene lists in (a) were validated using qRT-PCR in miR-320c HCT116 cells. Data are presented as mean ± S.E., 
n = 6. c. siRNA-mediated knockdown of FOXM1, FOXQ1, HMGB3, MKI67, RUNX1, SOX4 and ZWILCH led to significant reduction 
in HCT116 cell viability. Data are presented as mean ± S.E., n = 12. ***p < 0.0005. The two-tailed t-test was used to compare different 
treatment groups.
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HCT116 cells, strongly indicating these genes are potential 
targets for miR-320 family in CRC (Figure 3c).
mir-320c directly targets sOX4, FOXM1 and 
FOXQ1 in colorectal cancer
Three genes (SOX4, FOXM1, and FOXQ1) were 
subsequently chosen for further investigation based on 
their known role in colorectal or other human cancer 
types. Alignment of miR-320c and gene targets 3` UTR 
using TargetScan algorithm indicated two potential 
binding sites for SOX4 (position 1236-1242 and 2070-
2076), two binding sites for FOXM1 (position 862-868 
and 619-625), and one binding site for FOXQ1 (position 
614-621) (Figure 4a). Correspondingly, SOX4, FOXM1 
and FOXQ1 protein levels were decreased in miR-320c 
HCT116 compare to the LV control cells, indicating 
suppression of those genes at the protein level (Figure 4b). 
Importantly, the expression of SOX4, FOXM1, FOXQ1 
was inversely correlated to miR-320 levels in primary 
paired CRC patient samples, strongly indicating that all 
three genes are likely to be bona fide targets for miR-320 
(Figure 4c, 4d and 4e). Direct interaction between miR-
320c and the 3`UTR from SOX4, FOXM1 and FOXQ1 
was subsequently validated using a luciferase-based assay 
(Figure 4f). Taken together, these results demonstrated 
that downregulation of miR-320 family is a potential 
mechanism leading to the upregulation of SOX4, FOXM1 
and FOXQ1 in CRC.
Forced expression of mir-320c increase sensitivity 
of CRC cells to 5-fluorouracil
Our pathway analysis of downregulated genes 
in miR-320c-HCT116 cells revealed response to DNA 
damage as the sixth affected pathway, suggesting that 
over-expression of miR-320c might sensitize cancer cells 
to DNA damage inducing agents (Figure 2b). We therefore 
used the Acridine orange/Ethidium bromide assay to 
measure cell death in miR-320c HCT116 compared to 
LV control HCT116 cells in the presence of 5-FU. The 
concentration of 5-FU >3.125 µM was highly toxic to 
both cell groups; however using a lower concentration ( < 
3.125µM) induced more cell death in miR-320c HCT116 
compared to LV control HCT116 cells on day 5 (Figure 
5a). Concordantly, we also observed fewer colonies in 
miR-320c HCT116 + 5-FU compared to LV control 
HCT116 + 5-FU cells, suggesting that this combination 
might well be targeting the colony forming ability of these 
cells (Figure 5b and 5c).
mir-320c expression suppressed crc tumor 
growth in vivo
To demonstrate the biological relevance of miR-
320 on CRC tumorigenesis in vivo, miR-320c HCT116 or 
LV control HCT116 cells were implanted into immune-
deficient SCID mice that were monitored for tumor 
formation. Remarkable reduction in tumor growth was 
observed in the miR-320c HCT116 implants, thereby 
corroborating the in vitro data of miR-320c inhibition of 
clonogenicity (Figure 6a). Concordantly, mice implanted 
with the miR-320c HCT116 cells showed better survival 
compared to mice implanted with control cells (p = 
0.001, Figure 6b). Likewise, histological examination of 
xenograft tumors revealed a much greater degree of cell 
death (necrosis and apoptosis) in the miR-320c HCT116 
group (Figure 6c and 6d). Interestingly, interrogation 
of the expression of this identified gene panel (SOX4, 
FOXM1, and FOXQ1) in The Cancer Genome Atlas 
(TCGA) Colorectal cancer data set revealed significantly 
shorter disease-free survival in patients with elevated 
expression of these genes (Logrank Test P-Value: 0.00581, 
Figure 6e).  
DIscUssION
Carcinogenesis is a multi-step process arbitrated 
by multifaceted cascades of molecular events governing 
genomic alterations resulting in the cancer phenotype 
including uncontrolled cell proliferation [20]. Cumulative 
evidence revealed a functional involvement of specific 
miRNAs in cellular alteration and oncogenesis, and 
documented a pivotal pro- and anti- tumor role for specific 
miRNAs both in vitro and in vivo [21, 22]. Also, miRNA 
expression signatures have been proposed as diagnostic, 
prognostic or predictors of therapy response in different 
human cancers [21, 22]. Our recent work on CRC revealed 
multiple miRNA-mRNA regulatory networks, and have 
proposed loss and gain of several miRNAs as a key 
mechanism leading to CRC development and progression 
[10]. In the current study, we have identified several 
members of the miR-320 family to be downregulated in 
CRC. While a number of studies have implicated miR-
320 family in different human cancers, none to date has 
conducted such in-depth investigation of the role of this 
family of miRNAs in CRC. Therefore, in this current 
study, we had utilized an integrative approach utilizing 
stable lentiviral-mediated miRNA expression, gene 
expression microarrays, in silico prediction algorithms, in 
vitro and in vivo functional studies to identify clinically-
relevant novel gene targets for this family of miRNAs in 
CRC. Overexpression of miR-320c inhibited colon cancer 
cell proliferation, migration, colony formation, and in vivo 
tumor formation, elucidating a potent tumor suppressive 
role for this microRNA in CRC cells. Moreover, our data 
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Figure 4: Identification of SOX4, FOXM1 and FOXQ1 as bona fide targets for mir-320c. a. Illustration of the alignment 
of miR-320c and SOX4, FOXM1 and FOXQ1 3` UTR using TargetScan algorithm indicating potential binding sites. b. Immunoblotting 
showing downregulation of SOX4, FOXM1 and FOXQ1 protein in miR-320c HCT116 compared to control cells. Right panel presents 
quantification of band intensity. GAPDH was used as loading control. c., d. and e. Pearson correlation between the expression of target 
mRNAs (SOX4, FOXM1 and FOXQ1) and different members of the miR-320 family in thirteen pairs of CRC, corroborating SOX4, 
FOXM1 and FOXQ1 being a bona fide targets for miR-320 family in CRC. f. Luciferase-based reporter assay illustrating the direct 
interaction between miR-320c and the 3`UTR from SOX4, FOXM1 and FOXQ1. Data are presented as mean ± S.E., n = 5 from two 
experiments. The two-tailed t-test was used to compare different treatment groups.
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Figure 5: miR-320c sensitize CRC cells to 5-fluorouracil. a. Representative fluorescence images of miR-320c and LV control 
HCT116 cells (±different concentration (1.5-100 μM) 5-fluorouracil). Cells were stained with acridine orange/ethidium bromide to detect 
apoptotic (cells with green condensed chromatin) and necrotic cells (red) b. Representative clonogenic assay showing reduced clonogenicity 
of LV-miR-320c compared to LV control HCT116 cells (± 1.5 μM 5-fluorouracil). Plates were stained with Diff-Quik stain set on day 10. c. 
Cells were treated as in (b) in 6-well plate then the number of colonies was counted on day 10. Data are presented as mean colony number 
± S.D., n = 2. *p < 0.05.
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Figure 6: mir-320 expression suppresses crc growth in vivo. a. Tumour formation in SCID mice after subcutaneous injection 
of HCT116 cells stably-expressing miR-320c or LV control cells. Data are presented as mean (tumor volume) ± S.E., n = 6. Two-way 
ANONA analysis was used to compare the two growth curves. b. Mice in (a) were monitored and surviving fraction was plotted as 
function of time from tumor implantation. c., d. Representative histopathological examination of xenograft tumors from miR-320c and 
control HCT116 cells. FFPE sections were stained with haematoxylin and eosin stain. (Bar = 100 μm). e. Kaplan-Meier curves illustrate 
the duration of disease-free survival according to the expression of SOX4, FOXM1, or FOXQ1 panel in a cohort of 319 colorectal cancer 
patients. Using log-rank analysis; expression of SOX4, FOXM1, and FOXQ1 was associated with poor disease-free survival (p = 0.005). 
f. Schema illustrating the role of miR-320 family in CRC. Downregulation of miR-320 leads to up regulation of several genes involved in 
promoting CRC progression and drug resistance.
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are the first to reveal FOXQ1, and SOX4, and possibly 
HMGB3, MKI67, ZWILCH as novel targets for miR-320 
family in CRC. Furthermore, our data documented an 
inverse correlation between miR-320 family (miR-320a, 
b, c, d and e) with FOXM1, FOXQ1 and SOX4, in 13 
pairs of colon cancer tissues, thereby corroborating those 
genes as likely bona fide targets for miR-320 family and 
further implicating the miR-320/SOX4/FOXM1/FOXQ1 
axes in CRC. Interestingly, the clinical importance of this 
gene panel was further validated in the TCGA colorectal 
data set (319 patients) where elevated expression of this 
gene panel (SOX4, FOXM1, and FOXQ1) correlated with 
significantly shorter disease-free survival (Figure 6e).
Our current study corroborated previous studies that 
reported biological effects of miR-320 family in CRC. 
However, these studies have identified a different set of 
target genes. Sun et. al. reported that miR-320a inhibits the 
growth of CRC by targeting b-catenin signalling pathway 
[13]. Also Rac1 was identified as a direct target for miR-
320a in CRC [23]. Interestingly, Zang et. al. reported 
downregulation of miR-320d in colon cancer stem cells 
(CD133+) compared to CD133- cells in HT-29 CRC cells, 
which is concordant with our data implicating miR-320 
in regulating CRC tumor initiating cells using in vitro 
clonogenic and in vivo tumor formation assays [14]. 
In addition to CRC, aberrant expression of miR-320 
has been reported in several other types of human cancers. 
For instance, miR-320 was reported downregulated in 
malignant cholangiocarcinoma, which subsequently 
was found to negatively regulate Mcl-1 or Bcl-2 (anti-
apoptotic molecules) expression; in turn associated with 
chemotherapeutic drug-triggered apoptosis [24, 25]. In 
prostate cancer, overexpression of miR-320 blocked the 
Wnt/b-catenin pathway and reduced the cancer stem cell 
phenotype in the CD44high tumor-initiating cells [17]. 
Concordant with our data, Want et al recently implicated 
miR-320 in chemo-sensitivity by targeting FOXM1 in 
vitro, a critical gene which plays a principle role in colon, 
lung, and breast cancer tumor initiation and progression 
[26-28]. Similarly, other investigators have also shown 
that FOXQ1 played a key role in nasopharyngeal 
carcinoma, targeted by miR-506 and miR-124 [29, 30]; 
likewise, HMGB3 in breast cancer is targeted by miR-205 
[31]; and MKI67 in hepatocellular carcinoma, targeted by 
miR-519d [32]. 
In conclusion, based on our newly-generated data, 
we propose a model (see schema in Figure 6f), whereby 
loss of miR-320 family leads to increased levels of several 
miR-320 target genes, resulting in CRC progression, and 
drug resistance. Therefore, we would propose that miR-
320 mimics might serve as a potential therapeutic strategy 
in the future management of CRC. 
MAtErIALs AND MEtHODs
cells lines and tissue culture
 The human colorectal cancer (HCT116) cell line 
was obtained and subsequently was authenticated by 
Genetica DNA Laboratories, Inc. Burlington, (NC, USA). 
Cells were maintained in DMEM supplemented with 10% 
fetal bovine serum (Gibco-Invitrogen, Waltham, MA, 
USA) and 100 mg/L penicillin/streptomycin. All cells 
were maintained in a 37oC incubator with humidified 5% 
CO2.
Lentiviral transduction
 Lentiviral particles encoding for hsa-miR-320c-1 
(LP-HmiR0470-MR03-0200-S) or control lentiviral 
particles were purchased from Genecopoeia (Genecopoeia 
Inc., Rockville, MD, USA). Two hundred thousand 
HCT116 cells were seeded in complete DMEM in 24-well 
plate. Twenty-four hours later (~80 confluency), media 
was removed and then 20 μl of crude lentiviral particles in 
500 μl of DMEM+5% heat-inactivated serum (Invitrogen) 
and 1% Pen-Strep supplemented with polybrene (8 μg/
ml; Sigma, St. Louis, MO, USA) was added to the 
cells. Seventy-two hours later, media was removed and 
transduced cells were selected with puromycin (1 μg/
ml, Sigma, St. Louis, MO. USA) for 1 week until stably 
transduced cells were generated.
sirNA transfection
The siRNA-negative control, siSOX4, siFOXQ1, 
siFOXM1, siHMGB3, siRUNX1, siMKI67 and 
siZWILCH were purchased from Applied Biosystems 
(Invitrogen, Carlsbad, CA, USA). Transfection was 
performed using reverse transfection approach as 
described before [10, 33]. Briefly, 30 nM (final) siRNA 
was diluted in 50 μl of Opti-MEM (11058-021; Gibco, 
Carlsbad, CA, USA), whereas 1 μl of Lipofectamine 2000 
(Part No: 52758; Invitrogen) were diluted in 50 μl OPTI-
MEM. The diluted siRNA, and Lipofectamine 2000 were 
mixed and incubated at ambient temperature for 20 min. 
Twenty microliters of transfection mixture was added 
to the plate and subsequently 5,000 cells in transfection 
medium (routine culture medium without antibiotics) were 
added to each well in 60 μl volume. Every experiment 
was performed in 10 replicates in 96-well cell culture 
plates with the appropriate controls. The experiment 
was repeated at least two times. Plates were incubated 
for the indicated time points, and proliferation or growth 
inhibition was assessed using the alamarBlue (BUF012B; 
AbD Serotec, UK) assay.
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Gene expression microarray
RNA isolation, gene and microRNA expression 
experiments were performed in accordance with our 
previously published protocols [10, 34]. In brief, RNA 
was isolated using Total Tissue RNA Purification Kit 
from Norgen-Biotek Corp. (Thorold, ON, Canada) 
and were quantified using NanoDrop 2000 (Thermo 
Scientific, Wilmington, DE, USA). Total RNA was 
labelled and then hybridized to the Agilent Human 
SurePrint G3 Human GE 8 × 60 k v16 mRNA microarray 
chip (Agilent Technologies). All microarray experiments 
were conducted at the Microarray Core Facility (Stem 
Cell Unit, Department of Anatomy, King Saud University 
College of Medicine). Data were subsequently normalized 
and analyzed using GeneSpring 13.0 software (Agilent 
Technologies). Pathway analyses were conducted using 
the Single Experiment Pathway analysis feature in 
GeneSpring 13.0 (Agilent Technologies). Twofold cut-off 
with P < 0.02 was used. Target prediction was conducted 
using a built-in feature in GeneSpring 13.0 based on 
TargetScan database.
mrNA ad mirNA validation by qrt-Pcr
mRNAs expression levels were validated in 
LV control and miR-320c HCT116 cells using SYBR 
Green-based qRT-PCR and the Applied Biosystems 
ViiA 7 Detection system. 500 ng of total RNA was 
reverse transcribed using High Capacity cDNA Reverse 
Transcript Kit (Part No: 4368814; ABI) according to the 
manufacturer’s protocol. Relative levels of mRNA were 
determined from cDNA using real-time PCR (Applied 
Biosystems ViiA 7 System). Primer sequences used in 
the current study are listed in Supplementary Table 3. The 
relative expression level was calculated using -ΔΔCT. 
β-actin was used as an endogenous control. For miRNA 
validation, 10 ng of total RNA was reverse transcribed 
using TaqMan MicroRNA Reverse Transcription Kit 
(Part No: 4366596, ABI) and relative miRNA expression 
levels were determined using TaqMan Universal Master 
Mix II, no UNG (Part No: 4440040, ABI) and hsa-miR-
320c primers (ABI). The relative expression level was 
calculated using -ΔΔCT. RNU44 and RNU48 were used 
as endogenous control.
Measurement of cell viability and clonogenic 
assay
The viability of LV control and miR-320c 
HCT116 cells was determined using alamarBlue assay 
as previously described [10]. All assays were carried out 
with appropriate controls. Briefly, 5000 cells were cultured 
in a 96-well plate and cell viability was measured at the 
indicated time points by adding 10% volume alamarBlue 
assay reagent and measuring absorbance at 570λ . The 
colony forming ability of HCT116 cells transduced 
with miR-320c was determined using clonogenic assay 
as previously described [35, 36]. Briefly, LV control or 
miR-320c HCT116 cells were seeded in 12-well plates in 
different serial dilution (1:2 to 1:64). Initial seeding density 
was 0.015 X 106 cells per well, and incubated at 37oC 
under 5% CO2 for 10 days. The plates were then washed 
and stained with Diff-Quik stain set (Siemens), and the 
plates were scanned and number of colonies was observed 
under microscope. The fraction of surviving cells was 
estimated by comparison of miR-320c to LV control cells. 
The experiment was done twice in duplicate. Furthermore, 
the clonogenic assay was conducted to examine the effect 
of 5-Fluorouracil on colony formation in both cells. A total 
of 1 × 106 cells were seeded in T25 flask. After 48 hours 
of exposure to 1.5 µM of 5-Fluorouracil, the cells were 
trypsinized and reseeded in 12-well plates as described 
above to observe the effect of the drug. 
Immunoblotting
LV control and miR-320c HCT116 cells were lysed 
using RIPA buffer (Norgen-Biotek Corp.) containing 1 × 
Halt Protease Inhibitor Cocktail (Pierce Inc., Rockford, 
IL, USA). Thirty micrograms of total protein were run 
and blotted using the Bio-Rad V3 Western work flow 
system according to the manufacturer’s recommendation. 
Immunoblotting was conducted using anti-SOX4 rabbit 
polyclonal antibody (H-90, dilution 1:1000, Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-FOXM1 antibody 
263C2a (ab58675, dilution 1:400), and anti-FOXQ1 
antibody (ab51340, dilution 1:400), both from Abcam 
(Abcam, Cambridge, MA). Primary antibody was 
incubated overnight at 4 °C. Horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit (cat. no. 7074, 1:3000 
dilution; Cell Signaling) was used as the secondary 
antibody, whereas HRP-conjugated anti-GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) antibody 
(ab9482, 1:10000; Abcam, Cambridge, MA, USA) 
was used as the loading control. Quantification of band 
intensity was conducted using band quantification tool in 
Image Lab 5.0 software (Bio-Rad, CA, USA).
cell migration and proliferation
Real-time measurement of LV control and miR-320c 
HCT116 cell migration and proliferation was executed 
using the xCELLigence RTCA DP system (ACEA 
Biosciences, San Diego, CA). For migration study, cells 
were starved for 24 hrs in 1% serum media, followed by 
seeding 0.08X106 cells per well in 16-well microelectronic 
sensor plate pre-coated with fibronectin (1:500 dilution), 
two chamber trans-well plates (CIM-plate insert; ACEA 
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Bioscience) containing the respective serum conditions. 
Medium containing 10% serum (chemo-attractant) and 1% 
serum (control) was added to the bottom wells. 
For proliferation assay, cells were seeded (0.04X106 
cells/well) in two chamber plates (E-plate insert; ACEA 
Bioscience). Proliferation and migration of cells was 
measured from the interaction of cells with the electrodes 
on the top chamber and represented as a change in cell 
index (CI), an arbitrary unit derived from the relative 
change in electrical impedance across microelectronic 
sensor arrays. The electrical impedance was captured 
every 15 min for an experimental duration of ~100 hrs. 
The rate of migration and proliferation is expressed as 
the CI or the change in electrical impedance at each time-
point. The Cell Index at each time point is defined as 
(Rn-Rb)/4.6, where Rn is the cell-electrode impedance of 
the well when it contains cells and Rb is the background 
impedance of the well with the media alone. Values are 
expressed as the mean ± SEM of the 3 replica wells 
from three independent experiments. For conventional 
migration, the BD transwell migration system with 8 µ 
pore size was utilized. Inserts were placed in a 24-well 
plate, and 1.56x105 cells in 1% serum were added to the 
top of the chamber, and 10% serum added to the bottom 
chamber. Seventy-two hours later, inserts were fixed and 
stained with SIEMENNS DIFF-QUICK stain set (Siemens 
Healthcare Diagnostics), and the number of migrating 
cells was counted using a light microscope.
Luciferase reporter assay
For luciferase reporter assays, HEK293 cells were 
seeded in 12-well plates in 500µl complete DMEM 
growth medium without antibiotics. Second day when 
cells reached 80% confluency, cells were transfected 
with complexes containing control or UTR plasmid (100 
ng), pre-miR control or pre-miR-320c (50nM) mixed 
with lipofectamine 2000 (Part No: 52758; Invitrogen) 
in Opti-MEM (11058-021; Gibco, Carlsbad, CA, 
USA). Twenty-four hours after transfection, luciferase 
activity was measured using the Secrete-Pair™ Dual 
Luminescence assay kit (Secrete Gaussia luciferase (GLU) 
and Secreted Alkaline Phosphatase (SEAP); GeneCopeia 
Inc., USA) according to the manufacturer’s instructions 
while luminescence was subsequently measured using a 
SpectraMax M5 (Molecular Devices; USA) luminescence 
reader. The ratio of luminescence intensities of the GLU 
over SEAP was calculated and normalized to controls. 
Measurement of apoptosis
Fluorescence-based apoptosis was determined 
in cells after exposure to different concentration of 
5-Flurouracil, using acridine orange and ethidium bromide 
(AO/Etbr) staining method [37]. After treatment, the LV 
control and miR-320c HCT116 cells were stained with 
dual fluorescent staining solution containing 100 µg/
ml AO and 100 µg/ml EB (AO/EB, Sigma, St. Louis, 
MO). Cells were washed twice with PBS and were gently 
mixed with AO/EB (1:100) dye solution for one minute; 
afterwards, the cells were observed and photographed 
under a Nikon Eclipse Ti fluorescence microscope. Cells 
cultured without drug were considered as experiment 
control. Acridine Orange/Ethidium Bromide staining uses 
combination of two dyes to visualize cells with aberrant 
chromatin organization. The differential uptake of AO/EB 
allows the identification of viable and non-viable cells. 
Particularly, Acridine Orange was used to visualize the 
number of cells which has undergone apoptosis. 
In vivo tumorigenicity assay in scID mice
In vivo tumor formation was carried out as we 
previously described [9, 38]. Briefly, Six- to 8-week-old 
severe combined immunodeficient mice (SCID) were 
utilized for the xenograft experiments. Ten million LV 
control or miR-320c HCT116 cells were suspended in PBS 
and subcutaneously were injected into the right flank of 
SCID mice. Tumor size was measured twice weekly using 
a calliper and tumor volumes were calculated as (tumor 
length × width2)/2. At the end of the experiments, primary 
tumors were excised, fixed in 10% buffered formalin and 
embedded in paraffin and sectioned. Sections were stained 
with haematoxylin and eosin.
tcGA survival data analysis
Kaplan-Meier curve analysis for the expression of 
SOX4, FOXM1, and FOXQ1 in the TCGA colorectal 
cancer data set (319 patients) in relation to disease-free 
survival was conducted as previously described [39, 
40]. The log-rank test was used to determine statistical 
significance for curve comparison. 
statistical analysis
Statistical analyses and graphing were performed 
using Microsoft excel 2010 and GraphPad Prism 6.0 
software (GraphPad, San Diego, CA, USA). P-values 
were calculated using the unpaired two-tailed t-test. 
Pearson’s correlation was used to assess the correlation 
between SOX4, FOXM1, FOXQ1 and different members 
of the miR-320 family in CRC using the GraphPad Prism 
software.
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